It would be for all tests to 30 Sept, including those due say 20th Oct but unpaid.
Printable View
i guessed 3 sales based on us revenue on NZ$2k. That is revenue so would mean invoice issue, not necessarily paid. They may have received a few more pots of piss but not invoiced yet - it depends on their revenue recognition policy (refer DIL for complications companies face).
I also point out that guess is based on revenue. They may have done lots of free tests as part of user trials, new customer sign ups etc. I don't think the testers would have been doing nothing, waiting for the mail each day.
Here's the present sales status from the recent capital raising presentation for those who didn't participate. It does seem that the first significant sales fell just outside the HY reporting period, shame really, but it equally seems all a bit academic within a five year plan.
Attachment 5121
Ok thanks everyone.
Now what I get out of all that is the kits are sold for x dollars and the processing comes later at x dollars.
A bit like film processing back in the days when they did such things.
Do you get a free kit thrown in with your process results?:)
not convinced yet.., director are selling shares..take profit..indicating price is high enough
Capital raisings dust, lot’s to look forward to in 2014 when you pick through recent releases;
Announcements ahead, prospectively for Medicare/Medicaid, Veterans Association, Kaiser Permanente, Intermountain and perhaps other big insurers, probably a continuation of PPO’s coming on board too.
New markets, Europe through Oryzon in early 2014, Asia also, perhaps insurer agreements here too.
New products, Cxbladder (triage) scheduled to be ready in Q2, and Cxbladder (predict) in Q4.
There’s the $20.5M cash injection, sales team increasing from 4 to 20, initiating the 19 US sales territories.
Several US user programmes now complete should turn into ongoing orders, and the insurers may probably start demanding the anticipated clinical and economic benefits by prodding GP’s and urologists.
Hopefully some progress on the product pipeline, and that Queensland user programme to assess cxbladder as a replacement for ultrasound in a clinical setting.
A busy enough year ahead for PEB and investors both!
does anyone know what date we find out how many shares in total we were successful in obtaining in the recent rights issue?
and what date rights become tradable?
......so what has happened to NZ sales?, have they actually had any yet? (cant be many,if any, with total sales per week currently sitting at about $650!)
trading the rights has been and gone, i think we get allocated our shares on the 4th from memory, then you can trade the actual shares, i presume the rights may be removed from DB/ASB automatically but more likely you'll just have to delete them and update your holding with the number you have been granted/obtained